Clinicopathologic correlation of occult
choroidal neovascularization in age-related macular degeneration.
In Japan, EYLEA is approved for the treatment of visual impairment due to myopic
choroidal neovascularization, (wet) age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) and diabetic macular edema.
Ranibizumab is a prescription medicine used in treating people who are suffering from wet age-related macular degeneration (wAMD), DME, retinal vein occlusion (RVO), myopic
choroidal neovascularization.
Intravitreal bevacizumab for the treatment of
choroidal neovascularization secondary to pseudotumor cerebri.
Choroidal neovascularization (CNV) is the major cause of vision loss associated with angioid streaks.
One possible therapeutic approach to the development of abnormal blood vessels in proliferative diabetic retinopathy and central retinal vein occlusion,
choroidal neovascularization secondary to age related macular degeneration, and macular edema associated to various retinovascular diseases is to inhibit VEGF activity with a VEGF-blocking drug.
Previous authors have reported
choroidal neovascularization (CNV) associated to papilledema (3, 4, 5).
Despite having promising results in
choroidal neovascularization, diabetic retinopathy and macular edema there is no long-term information on safety of Avastin.
The differential diagnosis in leukemic patients with exudative retinal detachment includes central serous choroidopathy, uveal effusion syndrome,
choroidal neovascularization, Harada's syndrome, congenital optic disc pits.
Chapters have been rewritten to reflect recent diagnostic and therapeutic developments in the field and begin with anatomy and pathophysiology of the macula, followed by imaging, surgical techniques, and aspects and treatments for diabetic retinopathy, macular edema, vitreous traction maculopathies, macular holes,
choroidal neovascularization and age-related macular degeneration, infectious diseases of the macula, pediatrics, trauma, and tumors and miscellaneous conditions, ending with prevention and treatment of complications and future trends.
Shusheng Wang, assistant professor of ophthalmology and pharmacology and co-senior author of the study and colleagues found that silencing the microRNA cluster members miR-23 and miR-27 hindered the excessive formation of blood vessels in the back of the eye, known as
choroidal neovascularization.
Therapeutic manipulation of microRNAs 23 and 27 may give us a way to treat
choroidal neovascularization in patients with degenerative retinal diseases.
